Molbio Diagnostics IPO Details, Financials, Valuation & Peers
Explore Molbio Diagnostics IPO details, including IPO dates, financial statements, valuation, peer comparison and more.
Overview
Company Overview: Molbio Diagnostics Limited
Incorporated in 2000, Molbio Diagnostics Limited is a point-of-care (POC) diagnostics company focused on providing accurate, rapid, and cost-effective healthcare solutions for infectious and non-communicable diseases. The company serves public health programs, diagnostic laboratories, and hospitals through a business model driven by device sales and recurring revenue from proprietary test kits. Beyond molecular diagnostics, the company offers radiology, digital pathology, and breast health screening solutions through its subsidiaries and partners.
Key Highlights
- Innovative Platform: The company developed ‘Truenat,’ a portable PCR system that enables decentralized diagnosis within one hour, even in resource-limited settings.
- Broad Portfolio: As of March 31, 2025, the platform is patented in over 100 countries and supports molecular testing for 30 diseases across 42 assays, including tuberculosis, COVID, HIV, and HPV.
- WHO Recognition: The ‘Truenat’ tuberculosis test is one of only two WHO-endorsed rapid molecular tests for initial TB diagnosis and rifampicin resistance detection.
- Global Scale and Manufacturing: Operating five manufacturing facilities across India, the company maintains a presence in over 80 countries, with more than 10,000 devices sold globally as of March 31, 2025.
Objects of the Issue
- Funding capital expenditure towards the setting up of infrastructure for research and development facility, Center of Excellence and connected office space.
- Funding capital expenditure towards the purchase of certain plant, machinery and other equipment for Goa Unit I, Goa Unit II and Visakhapatnam Unit, and
- General Corporate Purposes
- Total
IPO Details
Discover essential information crucial for understanding an IPO, including the Price Band, Fresh Issue, Offer For Sale, Total IPO Size and more. Explore these key details to gain insight into the company's public offering.
| Fields | Details |
|---|---|
| IPO Dates | 10 Aug - 12 Aug 2026 |
| IPO Price Band | ₹768 - ₹807 per share |
| Fresh Issue | ₹200.00 crore |
| Offer For Sale | ₹739.70 crore |
| Total IPO Size | ₹939.70 crore |
| Face Value | ₹1 |
| Listing On | BSE, NSE |
IPO Timeline
Explore important dates like IPO opening, closing, listing and others, outlining the journey of the Public Offering. This will help you grasp the entire IPO journey effortlessly.
| Event | Date |
|---|---|
| IPO Opening Date | 10 Aug 2026 |
| IPO Closing Date | 12 Aug 2026 |
| Basis Of Allotment | 13 Aug 2026 |
| Refunds | 14 Aug 2026 |
| Demat Transfer | 14 Aug 2026 |
| IPO Listing Date | 17 Aug 2026 |
Financial Statements
Explore a comprehensive financial data table showcasing key metrics including revenue, expenses, net income, and others. Gain valuable insights about the company's financial performance at a glance, facilitating informed decision-making and strategic planning for subscribing to the IPO.
| Period Ended | 31 Mar 2024 | 31 Mar 2025 | 31 Mar 2026 |
|---|---|---|---|
| Assets | 1,221.06 | 1,461.56 | 2,148.42 |
| Total Income | 840.66 | 1,027.94 | 1,455.17 |
| Profit After Tax | 83.54 | 138.58 | 164.14 |
| EBITDA | 185.09 | 256.64 | 328.24 |
| NET Worth | 807.94 | 952.95 | 1,144.68 |
| Reserves and Surplus | 845.48 | 990.84 | 1,148.84 |
| Total Borrowing | 174.58 | 123.16 | 412.64 |
* NPM represents the net profit margin, calculated as a percentage. All other figures are presented in crore (₹cr)
Peer Comparison
Compare key financial metrics with industry peers to gain valuable insights into the company's performance compared to its competitors.
| Name | P/E | EPS | RoNW | NAV |
|---|---|---|---|---|
| Molbio Diagnostics Ltd. | 54.64 | 14.77 | 14.55% | 101.51 |
| Vijaya Diagnostic Centre Ltd | 81.02 | 16.79 | 18.07% | 93.02 |
| Metropolis Healthcare Ltd | 63.72 | 9.19 | 12.56% | 72.98 |
| Dr. Lal Pathlabs Ltd | 62.2 | 30.2 | 20.78% | 145 |
| Poly Medicure Ltd | 52.61 | 31.75 | 10.37% | 306.45 |
* Revenue in (₹cr), RoNW in (%), EPS, NAV in (₹). P/E ratio is based on the highest price from the IPO price band.
IPO Reservation
| Investor Type | Shares Offered |
|---|---|
| Retail Individual Investor (RII) | Not less than 35% of the Net Offer |
Subscription Data from NSE and BSE
As the issue has not yet opened, subscription data is unavailable. However, you can view subscriptions for other ongoing issues here.
IPO Registrar
KFin Technologies Limited
Phone: +91 40 6716 2222/ 18003094001
Email: einward.ris@kfintech.com
Website: www.kfintech.com
Lead Managers
- 1Kotak Mahindra Capital Co.Ltd.
- 2Motilal Oswal Investment Advisors Ltd.
- 3IIFL Capital Services Ltd.
- 4Jefferies India Pvt.Ltd.
Company Address
Molbio Diagnostics Ltd.Plot No. L-46
Phase II-D, Verna Industrial Area
Verna, Salcete
South Goa, Goa – 403722
Website: https://www.molbiodiagnostics.com/
Phone: 8326724888
FAQs
- What is the issue size of the Molbio Diagnostics IPO?The Molbio Diagnostics IPO has an issue size of ₹939.70 crore. This includes a fresh issue of ₹200.00 crore and an offer for sale (OFS) of ₹739.70 crore.
- What is the price band of the Molbio Diagnostics IPO?The price band for the Molbio Diagnostics IPO is ₹768 - ₹807 per share.
- What are the bidding dates for the Molbio Diagnostics IPO?The Molbio Diagnostics IPO will open for bidding on 10 Aug 2026 and close on 12 Aug 2026.
- What is the allotment date for the Molbio Diagnostics IPO?The allotment date for the Molbio Diagnostics IPO is 13 Aug 2026.
- What is the listing date for the Molbio Diagnostics IPO?The listing date for the Molbio Diagnostics IPO is 17 Aug 2026.
- What is the Molbio Diagnostics IPO grey market premium?The grey market premium (GMP) for the Molbio Diagnostics IPO is currently at ₹180, with an expected listing gain of approximately 22.3%. Remember, the grey market premium is not an official indicator, but it reflects market perception and demand for the IPO shares.